Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050645 | 0.90 | KDM4E (0.44) | KDM4EMEN1KMT2APOLBHSD17B10 | |
| SCHEMBL4097705 | 0.90 | TP53 (0.48) | POLBMAPTSMN1; SMN2 | |
| SCHEMBL1046780 | 0.90 | PPARG (0.44) | KDM4EMEN1KMT2APOLBHSD17B10 | |
| SCHEMBL1045315 | 0.89 | PTGDR2 (0.43) | MEN1KMT2APPARGKCNK3PTGDR2 | |
| SCHEMBL1048090 | 0.89 | MEN1 (0.52) | KDM4EMEN1KMT2APOLBHSD17B10 | |
| SCHEMBL1049440 | 0.88 | PTGER4 (0.43) | KDM4EKMT2AKCNK3PTGDR2PTGER4 | |
| SCHEMBL1050201 | 0.86 | PTGDR2 (0.44) | MEN1KMT2AMAPTKCNK3PTGDR2 | |
| SCHEMBL5318767 | 0.85 | PPARG (0.41) | KDM4EMAPTPPARGKCNK3PTGDR2 | |
| SCHEMBL1049751 | 0.84 | CYP1A2 (0.46) | PTGDR2PTGER4 | |
| SCHEMBL1047214 | 0.84 | PTGDR2 (0.40) | KDM4EKCNK3PTGDR2PTGER4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502624-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | THE UNIVERSITY OF KANSAS (US) | 2012-09-26 | — | — | EP | claimed |
| EP-1786424-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | The University of Kansas (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060047126-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-02 | — | — | US | claimed |
| WO-2006023704-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | UNIVERSITY OF KANSAS (US) | 2006-03-02 | — | — | WO | claimed |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | THE UNIVERSITY OF KANSAS (US) | 2013-05-16 | — | — | US | disclosed |
| US-8377958-B2 | Lonidamine analogues for fertility management | THE UNIVERSITY OF KANSAS (US) | 2013-02-19 | — | — | US | disclosed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2451783-A2 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | University Of Kansas (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS | 2011-03-10 | — | — | US | disclosed |
| WO-2011005759-A2 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047126-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | TRAP1, HSPE1, HSF1 | KDM4E 1905/4885MEN1 1637/4885KMT2A 3243/4885 |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | KDM4E 2309/4885MEN1 1440/4885KMT2A 1947/4885 |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, RAF1 | KDM4E 3466/4885MEN1 3432/4885KMT2A 1745/4885 |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | KDM4E 2309/4885MEN1 1440/4885KMT2A 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.